Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2259-86-1

Post Buying Request

2259-86-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2259-86-1 Usage

Description

H-LYS(ME)2-OH HCL, also known as N,N,N'-Trimethyl-L-lysine hydrochloride, is an L-lysine derivative with two methyl substituents attached to the side-chain amino group. It is a white powder and is a promising compound with various applications in different industries.

Uses

Used in Pharmaceutical Industry:
H-LYS(ME)2-OH HCL is used as an active pharmaceutical ingredient for its potential therapeutic effects. The compound may have applications in the treatment of various diseases due to its unique chemical structure and properties.
Used in Cosmetic Industry:
H-LYS(ME)2-OH HCL is used as an ingredient in the cosmetic industry for its potential benefits in skin care products. The compound may contribute to improved skin health and appearance due to its unique properties.
Used in Research and Development:
H-LYS(ME)2-OH HCL is used as a research compound for studying its chemical properties and potential applications in various fields. The compound may be valuable in the development of new drugs, materials, or technologies.
Used in Chemical Synthesis:
H-LYS(ME)2-OH HCL is used as a building block in the synthesis of more complex molecules. Its unique structure and properties make it a valuable starting material for the development of new compounds with specific functions or applications.
Used in Analytical Chemistry:
H-LYS(ME)2-OH HCL is used as a reference compound or standard in analytical chemistry for the identification and quantification of related compounds. Its well-defined structure and properties make it an ideal candidate for such applications.

Check Digit Verification of cas no

The CAS Registry Mumber 2259-86-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,5 and 9 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 2259-86:
(6*2)+(5*2)+(4*5)+(3*9)+(2*8)+(1*6)=91
91 % 10 = 1
So 2259-86-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H18N2O2/c1-10(2)6-4-3-5-7(9)8(11)12/h7H,3-6,9H2,1-2H3,(H,11,12)/t7-/m0/s1

2259-86-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name N6,N6-dimethyl-L-lysine

1.2 Other means of identification

Product number -
Other names Nepsilon-Dimethyl-L-lysine hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2259-86-1 SDS

2259-86-1Relevant articles and documents

Binding Methylarginines and Methyllysines as Free Amino Acids: A Comparative Study of Multiple Host Classes**

Warmerdam, Zoey,Kamba, Bianca E.,Le, My-Hue,Schrader, Thomas,Isaacs, Lyle,Bayer, Peter,Hof, Fraser

, (2021/11/30)

Methylated free amino acids are an important class of targets for host-guest chemistry that have recognition properties distinct from those of methylated peptides and proteins. We present comparative binding studies for three different host classes that are each studied with multiple methylated arginines and lysines to determine fundamental structure-function relationships. The hosts studied are all anionic and include three calixarenes, two acyclic cucurbiturils, and two other cleft-like hosts, a clip and a tweezer. We determined the binding association constants for a panel of methylated amino acids using indicator displacement assays. The acyclic cucurbiturils display stronger binding to the methylated amino acids, and some unique patterns of selectivity. The two other cleft-like hosts follow two different trends, shallow host (clip) following similar trends to the calixarenes, and the other more closed host (tweezer) binding certain less-methylated amino acids stronger than their methylated counterparts. Molecular modelling sheds some light on the different preferences of the various hosts. The results identify hosts with new selectivities and with affinities in a range that could be useful for biomedical applications. The overall selectivity patterns are explained by a common framework that considers the geometry, depth of binding pockets, and functional group participation across all host classes.

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. 2. Synthesis and structure-activity relationships of α,α-cycloalkylglycine sulfonamides

Fattori, Daniela,Rossi, Cristina,Fincham, Christopher I.,Caciagli, Valerio,Catrambone, Fernando,D'Andrea, Piero,Felicetti, Patrizia,Gensini, Martina,Marastoni, Elena,Nannicini, Rossano,Paris, Marielle,Terracciano, Rosa,Bressan, Alessandro,Giuliani, Sandro,Maggi, Carlo A.,Meini, Stefania,Valenti, Claudio,Quartara, Laura

, p. 550 - 565 (2007/10/03)

Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2259-86-1